Bachem Holding AG Class B (GB:0QND)
LSE:0QND
0QND Stock Chart & Stats
CHF65.96
CHF0.36(0.61%)
At close: 4:00 PM EST
CHF65.96
CHF0.36(0.61%)
Day’s Range― - ―
52-Week RangeCHF45.46 - CHF76.00
Previous CloseN/A
Volume89.00
Average Volume (3M)23.67K
Market Cap
CHF4.98B
Enterprise ValueCHF5.00B
Total Cash (Recent Filing)CHF30.99M
Total Debt (Recent Filing)CHF57.39M
Price to Earnings (P/E)30.2
Beta1.02
Next Earnings
Jul 21, 2026EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend Yield1.49%
Share Statistics
EPS (TTM)1.32
Shares Outstanding75,000,000
10 Day Avg. Volume22,257
30 Day Avg. Volume23,672
Financial Highlights & Ratios
PEG Ratio1.27
Price to Book (P/B)3.08
Price to Sales (P/S)6.46
P/FCF Ratio-93.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF84.20Price Target Upside27.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)2.38
Revenue Forecast (FY)CHF949.88M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a growing equity base give Bachem durable financial flexibility. Low debt reduces interest burden and supports capital allocation for capacity, R&D, or acquisitions without stressing liquidity, strengthening resilience over the next 2–6 months.
High And Resilient ProfitabilitySustained net margins near 20% and healthy operating profitability indicate structural pricing power and efficient operations in peptide CDMO. This margin base supports reinvestment, covers operating needs, and buffers earnings through cyclical project timing over a multi-month horizon.
Recurring CDMO Revenue ModelBachem’s model combines development-stage services with long-term commercial supply contracts. Successful R&D-to-commercial transitions create durable, recurring revenue streams and visibility from multi-year supply agreements, reducing revenue volatility over medium term.
Bears Say
Persistent Negative Free Cash FlowRecurring negative free cash flow signals that investment and working-capital needs consistently absorb operating cash. Over 2–6 months this limits internal funding for growth or distributions, may force financing, and raises scrutiny on capital allocation efficiency.
Inconsistent Cash ConversionUneven conversion of accounting profits into cash complicates forecasting and weakens financial predictability. This inconsistency can force timing mismatches between revenues and cash needs, increasing reliance on external financing or constraining discretionary investments in the near term.
Margin Drift Versus Prior PeaksGradual margin compression relative to 2021–2022 suggests pressure from cost, pricing, or mix shifts (e.g., more clinical-stage work). If the trend continues it would erode return on capital and reduce ability to fund growth internally across the medium term.
Bachem Holding AG News
0QND FAQ
What was Bachem Holding AG Class B’s price range in the past 12 months?
Bachem Holding AG Class B lowest share price was CHF45.46 and its highest was CHF76.00 in the past 12 months.
What is Bachem Holding AG Class B’s market cap?
Bachem Holding AG Class B’s market cap is CHF4.98B.
When is Bachem Holding AG Class B’s upcoming earnings report date?
Bachem Holding AG Class B’s upcoming earnings report date is Jul 21, 2026 which is in 101 days.
How were Bachem Holding AG Class B’s earnings last quarter?
Bachem Holding AG Class B released its earnings results on Mar 12, 2026. The company reported CHF1.317 earnings per share for the quarter, beating the consensus estimate of CHF0.88 by CHF0.437.
Is Bachem Holding AG Class B overvalued?
According to Wall Street analysts Bachem Holding AG Class B’s price is currently Undervalued.
Does Bachem Holding AG Class B pay dividends?
Bachem Holding AG Class B pays a Annually dividend of CHF0.85 which represents an annual dividend yield of 1.49%. See more information on Bachem Holding AG Class B dividends here
What is Bachem Holding AG Class B’s EPS estimate?
Bachem Holding AG Class B’s EPS estimate is 0.73.
How many shares outstanding does Bachem Holding AG Class B have?
Bachem Holding AG Class B has 75,000,000 shares outstanding.
What happened to Bachem Holding AG Class B’s price movement after its last earnings report?
Bachem Holding AG Class B reported an EPS of CHF1.317 in its last earnings report, beating expectations of CHF0.88. Following the earnings report the stock price went up 13.66%.
Which hedge fund is a major shareholder of Bachem Holding AG Class B?
Currently, no hedge funds are holding shares in GB:0QND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bachem Holding AG Class B
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
0QND Stock 12 Month Forecast
Average Price Target
CHF84.20
▲(27.65% Upside)
Technical Analysis
Lonza Group Ltd
―
Siegfried Holding AG
―
Ypsomed Holding AG
―
PolyPeptide Group AG
―
Galenica AG
―
Options Prices
Currently, No data available
---